Hormone Therapy & PORT for Low-Risk Prostate Cancer: No Survival Benefit Found | New Research
For many men undergoing radiotherapy after prostate cancer surgery, adding hormone therapy may not improve survival, particularly if their post-operative prostate specific antigen (PSA) levels are low. This finding, stemming from a large meta-analysis of individual patient data, challenges long-held assumptions about the benefits of hormone therapy in this context and could spare many patients from unnecessary treatment and its associated side effects.
The research, published in The Lancet and presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, analyzed data from over 6,000 men who received postoperative radiotherapy (PORT) following a radical prostatectomy. The study compared outcomes for those who too received hormone therapy – either short-term (4-6 months) or long-term (24 months) – with those who received radiotherapy alone. Researchers, led by Amar Kishan at UCLA, found no significant difference in overall survival between the groups for men with a PSA of 0.5 ng/mL or less. Inside Precision Medicine reports on the findings.
Understanding PSA Levels and Recurrence
Prostate specific antigen (PSA) is a protein produced by the prostate gland. Elevated PSA levels after surgery can indicate remaining cancer cells. Following a radical prostatectomy – surgical removal of the prostate – some men experience a recurrence of cancer, detectable through rising PSA levels. Hormone therapy, also known as androgen deprivation therapy (ADT), aims to lower testosterone levels, as prostate cancer cells often rely on testosterone to grow. Traditionally, hormone therapy has been used alongside radiotherapy to improve outcomes in men with recurrent prostate cancer. However, this study questions that practice for many.
Nuance in the Findings: When Hormone Therapy *May* Help
The study wasn’t a blanket dismissal of hormone therapy’s role. The researchers observed a clear distinction based on PSA levels. For men with a PSA between 0.51, and 1.00 ng/mL, those who received hormone therapy in addition to radiotherapy had a significantly higher 10-year overall survival rate (80.9%) compared to those who received radiotherapy alone (76.4%). This benefit became even more pronounced for men with PSA levels above 1.00 ng/mL, with survival rates of 80.5% versus 72.4%, respectively. The European Society for Medical Oncology (ESMO) highlights this critical distinction.
Study Design and Limitations
The POSEIDON study was a meta-analysis, meaning it pooled data from six previously conducted randomized, phase III clinical trials. This approach increases statistical power and provides a more comprehensive picture than any single trial could offer. However, it’s important to acknowledge the limitations inherent in meta-analyses. The original trials were designed with varying methodologies and endpoints, which could introduce some degree of bias. The study focused on overall survival, and did not extensively examine other important outcomes such as quality of life or the time to cancer progression. The authors themselves note the need to identify biomarkers that could predict which patients are most likely to benefit from hormone therapy.
What In other words for Patients
For men with low PSA levels (0.5 ng/mL or less) after prostatectomy, these findings suggest that radiotherapy alone may be sufficient to control the recurrence of cancer. Avoiding hormone therapy in these cases could significantly reduce the burden of treatment, as ADT can cause a range of side effects, including fatigue, hot flashes, sexual dysfunction, and bone loss. However, this does *not* mean hormone therapy is universally unnecessary. The study clearly demonstrates a potential benefit for men with higher PSA levels.
It’s crucial to emphasize that treatment decisions should always be made in consultation with a qualified oncologist, taking into account individual patient characteristics, risk factors, and preferences. This research provides valuable information to inform those discussions, but it does not replace personalized medical advice.
The Role of Biomarkers and Future Research
The authors of the study emphasize the need for further research to identify biomarkers – measurable indicators of a biological state – that can predict which patients are most likely to benefit from hormone therapy. Currently, PSA level is the best available predictor, but it’s not perfect. Identifying more precise biomarkers could allow clinicians to tailor treatment strategies more effectively, maximizing benefits whereas minimizing unnecessary side effects. Ongoing and future clinical trials will likely focus on exploring potential biomarkers and refining treatment protocols for recurrent prostate cancer.
Guidance Updates and the Path Forward
While this study provides strong evidence, it’s unlikely to lead to immediate, sweeping changes in clinical practice. Guidelines from organizations like the National Comprehensive Cancer Network (NCCN) are typically updated based on a comprehensive review of the available evidence. It’s reasonable to expect that these guidelines will be re-evaluated in light of the POSEIDON study’s findings. Drugs.com reports that the researchers saw no significant interaction between the duration of hormone therapy and its effect.
In the meantime, clinicians are likely to incorporate these findings into their decision-making process, carefully considering PSA levels and individual patient factors when determining whether to recommend hormone therapy alongside radiotherapy. Continued surveillance of treatment outcomes and ongoing research will be essential to refine our understanding of the optimal management of recurrent prostate cancer.